Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir

Antiviral Chemistry and Chemotherapy

Volumn 11, Issue 4, 2000, Pages 303-309

  Smee, Donald F ^a   Bailey, Kevin W ^a   Sidwell, Robert W ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral; Bioterrorism; Cidofovir; Cowpox virus; Ribavirin

Indexed keywords

CIDOFOVIR; PLACEBO; RIBAVIRIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL WARFARE; CONTROLLED STUDY; COWPOX; COWPOX VIRUS; DRUG EFFICACY; LUNG WEIGHT; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SURVIVAL RATE; VIRUS TITRATION;

EID: 0033854233     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020001100406     Document Type: Article

References (21)

1. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E & Huggins JW (2000) Cidofovir (HPMPC) protects mice against lethal aerosol or intranasal cowpox virus challenge. Journal of Infectious Diseases 181:10-19.
2. Breman JG & Henderson DA (1998) Poxvirus dilemmas - monkeypox, smallpox and biological terrorism. New England Journal of Medicine 339:556-559.
3. De Clercq E, Luczak M, Shugar D, Torrence PF, Waters JA & Witkop B (1976) Effect of cytosine arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proceedings of the Society for Experimental Biology and Medicine 151:487-490.
4. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P & Corrocher R (2000) Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31:997-1004.
5. Hillyard IW (1980) The preclinical toxicology and safety of ribavirin. In Ribavirin, a Broad Spectrum Antiviral Agents. Edited by RA Smith & W Kirkpatrick. New York: Academic Press. pp. 59-71.
6. Huffman JH, Sidwell RW, Khare GF, Witkowski JT, Allen LB & Robins RK (1973) In vitro effect of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrobial Agents and Chemotherapy 3:235-241.
7. Jolley WB & Hinshaw DB (1980) Minimal effects of ribavirin on the immune system. In Ribavirin, a Broad Spectrum Antiviral Agent. Edited by RA Smith & W Kirkpatrick. New York: Academic Press. pp. 73-81
8. Kesson AM, Ferguson JK, Rawlinson WD & Cunningham AL (1997) Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clinical Infectious Diseases 25:911-914.
9. Martinez MJ, Bray MP & Huggins JW (2000) A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Archives of Pathology and Laboratory Medicine 124:362-377.
10. Mills J (1999) Prevention and treatment of respiratory syncytial virus infections. Advances in Experimentai Medicine and Biology 458:39-53.
11. Moradpour D & Blum HE (1999) Current and evolving therapies for hepatitis C. European Journal of Gastroenterology and Hepatology 11:1199-1202.
12. Neyts J & De Clercq E (1993) Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. Journal of Medical Virology 41:242-246.
13. Orent W (1998) Escape from Moscow. The Sciences 1998:26-31.
14. Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PE, Falloon J, Davey RT Jr, Kovacs JA, Walker RE, Whitcup SM, Nussenblatt RB, Lane HC & Masur H (1995) Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrobial Agents and Chemotherapy 39:882-886.
15. Plosker GL & Noble S (1999) Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs 58:325-345.
16. Rizzetto M (1999) Therapy of chronic viral hepatitis: a critical view. Italian Journal of Gastroenterology and Hepatology 31:781-793.
17. Sidwell RW, Allen LB, Khare GP, Huffman JH, Witkowski JT, Simon LN & Robins RK (1973) Effect of 1-β-D-ribofuranosyl1,2,4-triazole-3-carboxamide (Virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrobial Agents and Chemotherapy 3:242-246.
18. Smee DF, Alaghamandan HA, Gilbert J, Burger RA, Jin A, Sharma BS, Ramasamy K, Revankar GR, Cottam HB, Jolley WB & Robins RK (1991) Immunoenhancing properties and antiviral activity of 7-deazaguanosine in mice. Antimicrobial Agents and Chemotherapy 35:152-157.
19. Smee DF, Bailey KW, Wong M-H & Sidwell RW (2000) Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Research (in press)
20. Smee DF & Huggins JW (1998) Potential of the IMP dehydrogenase inhibitors for antiviral therapies of poxvirus infections. Antiviral Research 37:A89.
21. Wachsman M, Petty BG, Cundy KC, Jaffe HS, Fisher PE, Pastelak A & Lietman PS (1996) Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Research 29:153-161.